US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4235877A
(en)
|
1979-06-27 |
1980-11-25 |
Merck & Co., Inc. |
Liposome particle containing viral or bacterial antigenic subunit
|
SE8205892D0
(en)
|
1982-10-18 |
1982-10-18 |
Bror Morein |
IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
AU614755B2
(en)
|
1987-06-05 |
1991-09-12 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Autocrine motility factors in cancer diagnosis and management
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5308854A
(en)
|
1990-06-18 |
1994-05-03 |
Merck & Co., Inc. |
Inhibitors of HIV reverse transcriptase
|
EP0468520A3
(en)
|
1990-07-27 |
1992-07-01 |
Mitsui Toatsu Chemicals, Inc. |
Immunostimulatory remedies containing palindromic dna sequences
|
US5187074A
(en)
|
1990-10-11 |
1993-02-16 |
Merck & Co., Inc. |
Method of hydroxylation with ATCC 55086
|
US5192668A
(en)
|
1990-10-11 |
1993-03-09 |
Merck & Co., Inc. |
Synthesis of protease inhibitor
|
WO1993008184A1
(en)
|
1991-10-23 |
1993-04-29 |
Merck & Co., Inc. |
Hiv protease inhibitors
|
US5413999A
(en)
|
1991-11-08 |
1995-05-09 |
Merck & Co., Inc. |
HIV protease inhibitors useful for the treatment of AIDS
|
KR100278157B1
(en)
|
1992-06-25 |
2001-01-15 |
장 스테판느 |
Vaccine Compositions Containing Supplements
|
US5665720A
(en)
|
1992-08-07 |
1997-09-09 |
Merck & Co., Inc. |
Benzoxazinones as inhibitors of HIV reverse transcriptase
|
DK0812593T4
(en)
|
1993-03-23 |
2008-05-13 |
Smithkline Beecham Biolog |
Vaccine preparations containing 3-O-deacylated monophosphoryl lipid-A
|
AU7973994A
(en)
|
1993-10-13 |
1995-05-04 |
Merck & Co., Inc. |
Combination therapy for hiv infection
|
SK281944B6
(en)
|
1993-11-17 |
2001-09-11 |
Laboratoires Om S. A. |
Beta(1->6)glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5476874A
(en)
|
1994-06-22 |
1995-12-19 |
Merck & Co., Inc. |
New HIV protease inhibitors
|
UA56132C2
(en)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
|
GB9620795D0
(en)
|
1996-10-05 |
1996-11-20 |
Smithkline Beecham Plc |
Vaccines
|
EP0761819A1
(en)
*
|
1995-09-12 |
1997-03-12 |
BEHRINGWERKE Aktiengesellschaft |
Exopolysaccharides of burkholderia pseudomallei and burkholderia mallei
|
US5666153A
(en)
|
1995-10-03 |
1997-09-09 |
Virtual Shopping, Inc. |
Retractable teleconferencing apparatus
|
US5846978A
(en)
|
1996-05-02 |
1998-12-08 |
Merck & Co., Inc. |
HIV protease inhibitors useful for the treatment of AIDS
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
GB9711990D0
(en)
|
1997-06-11 |
1997-08-06 |
Smithkline Beecham Biolog |
Vaccine
|
AU7924598A
(en)
|
1998-06-08 |
1999-12-30 |
Sca Emballage France |
Fast flattening packaging
|
DK1091928T3
(en)
|
1998-06-30 |
2007-07-23 |
Om Pharma |
Novel acylated pseudodipeptides, processes for their preparation and compositions containing them
|
FR2782721B1
(en)
|
1998-09-01 |
2000-11-03 |
Inst Nat Sante Rech Med |
NOVEL PHOSPHOHALOHYDRIN COMPOUNDS, MANUFACTURING METHOD AND APPLICATIONS
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
CZ303515B6
(en)
|
1999-04-19 |
2012-11-07 |
Smithkline Beecham Biologicals S. A. |
Adjuvant compositions
|
AU1581400A
(en)
|
1999-12-22 |
2001-07-03 |
Om Pharma |
Acyl pseudopeptides bearing a functionalised auxiliary spacer
|
PT1408984E
(en)
*
|
2001-07-20 |
2008-12-26 |
Bioagency Ag |
Organo-phosphorous compounds for activating gamma/delta t cells
|
WO2005021708A2
(en)
*
|
2003-05-16 |
2005-03-10 |
University Of Maryland Biotechnology Institute |
Bisphosphonates for prophylaxis and therapy against bioterrorism agents
|
WO2006067635A2
(en)
*
|
2004-12-20 |
2006-06-29 |
Innate Pharma S.A. |
USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
|
WO2006103568A2
(en)
|
2005-03-22 |
2006-10-05 |
Innate Pharma |
NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF
|
GB0519871D0
(en)
*
|
2005-09-30 |
2005-11-09 |
Secr Defence |
Immunogenic agents
|
GB0615635D0
(en)
*
|
2006-08-07 |
2006-09-13 |
Secr Defence |
Immunogenic proteins and uses thereof
|
EP2368568A1
(en)
*
|
2006-11-01 |
2011-09-28 |
Immport Therapeutics, INC. |
Compositions and methods for immunodominant antigens
|
WO2008146167A2
(en)
*
|
2007-06-01 |
2008-12-04 |
Innate Pharma S.A. |
Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
|
EP2123285A1
(en)
*
|
2008-05-21 |
2009-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
|